DPP
DrugDaily, single, co-formulated, FTC/TDF + combined ethinyl estradiol/levonorgestrel oral contraceptive pill
NCT Number: NCT07288190
To evaluate adherence to a single dual-prevention pill (DPP) compared with a two-pill regimen (2PR) for pre-exposure prophylaxis (PrEP) and pregnancy prevention in women without HIV.
Trial opening soon.
Get Notified16 year–39 year
Female
Interventional
Phase 2
Eswatini Prevention Center CRS, Mbabane, Eswatini
To evaluate adherence to a single DPP consisting of co-formulated Tenofovir Disoproxil Fumarate and Emtricitabine (FTC/TDF) plus combined ethinyl estradiol/levonorgestrel oral contraceptive (COC), compared with a two-pill regimen (2PR) consisting of daily oral FTC/TDF pill and combined COC pill, for pre-exposure prophylaxis PrEP and pregnancy prevention in women without HIV.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily, single, co-formulated, FTC/TDF + combined ethinyl estradiol/levonorgestrel oral contraceptive pill
Daily, two-pill regimen of oral FTC/TDF and ethinyl estradiol/levonorgestrel oral contraceptive pill
Choice of either DPP or 2PR
Time frame: Week 12
Intraerythrocytic Tenofovir Diphosphate (TFV-DP) concentrations in dried blood spot (DBS)
Time frame: Week 12
Intraerythrocytic TFV-DP concentrations in DBS
Time frame: Week 24
Intraerythrocytic TFV-DP concentrations in DBS
Time frame: Week 24
Intraerythrocytic TFV-DP concentrations in DBS
Time frame: Week 48
TFV-DP concentrations in DBS
Time frame: Week 48
TFV-DP concentrations in DBS
Time frame: Week 48
Self-reported adherence
Time frame: Week 48
Self-reported adherence
Time frame: Week 24
Answers to acceptability questionnaire based on overall acceptability measure as well as a range of acceptability dimensions (e.g., product size, color, dosing, etc.)
Time frame: Week 24
Answers to acceptability questionnaire based on overall acceptability measure as well as a range of acceptability dimensions (e.g., product size, color, dosing, etc.)
Time frame: Week 48
Answers to acceptability questionnaire based on overall acceptability measure as well as a range of acceptability dimensions (e.g., product size, color, dosing, etc.)
Time frame: Week 48
Acceptability of 2PR based on answers to acceptability questionnaire based on overall acceptability measure as well as a range of acceptability dimensions (e.g., product size, color, dosing, etc.)
Time frame: Day 0
Preference of DPP at enrollment
Time frame: Week 24
Preference of DPP at completion of the crossover phase of the study
Time frame: Day 0
Preference of 2PR at enrollment
Time frame: Week 24
Preference of 2PR at completion of the crossover phase of the study
Time frame: Week 48
Proportion of participants still using their chosen regimen at end of the Choice period
Time frame: Week 48
Proportion of participants still using their chosen regimen at end of the Choice period
Time frame: Week 48
Tolerability
Time frame: Week 48
Tolerability
Time frame: Week 24
Tolerability
Time frame: Week 24
Tolerability
Time frame: Week 48
Tolerability
Time frame: Week 48
Tolerability
Time frame: Week 48
Grade 2+ Adverse Events (AE)
Time frame: Week 48
Grade 2+ AE
Time frame: Week 24
Grade 2+ AE
Time frame: Week 24
Grade 2+ AE
Time frame: Week 48
Grade 2+ AE
Time frame: Week 48
Grade 2+ AE
Time frame: Week 48
Intimate Partner Violence (IPV)
Time frame: Week48
IPV
Time frame: Week 24
IPV
Time frame: Week 24
IPV
Time frame: Week 48
IPV
Time frame: Week 48
IPV
Time frame: Week 48
Pregnancy
Time frame: Week 48
Pregnancy
Time frame: Week 24
Pregnancy
Time frame: Week 24
Pregnancy
Time frame: Week 48
Pregnancy
Time frame: Week 48
Pregnancy
Time frame: Week 48
HIV incidence
Time frame: Week 48
HIV incidence
Time frame: Week 24
HIV incidence
Time frame: Week 24
HIV incidence
Time frame: Week 48
HIV incidence
Time frame: Week 48
HIV incidence
Contact information is provided by the study sponsor or research team.
Michelle Robinson
CONTACT
Scott Rose
CONTACT
HIV Prevention Trials Network
Network
A Multisite, Open-label, Randomized Crossover Study Comparing Adherence to a Single Daily Dual Prevention Pill (DPP) Versus FTC/TDF and Combined Oral Contraception Separate Pill Dosing (2PR), Given for Pre-exposure Prophylaxis and Pregnancy Prevention in Women
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02447159
Behavior, Blood-Borne Infections
Eket, Akwa Ibom State, Nigeria
View Trial DetailsNCT05541081
Bacterial Infections, Bacterial Infections and Mycoses
Harare, Zimbabwe
View Trial DetailsNCT00894257
Blood-Borne Infections, Communicable Diseases
Montpellier, France
View Trial DetailsNCT00000808
AIDS-Related Complex, Acquired Immunodeficiency Syndrome
La Jolla, California, United States
View Trial Details